ArticleThe British journal of radiology2012
Radiation damage and radioprotectants: new concepts in the era of molecular medicine.
Article in The British journal of radiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 142 citations in OpenAlex.
- Famotidine as a radioprotector for rectal mucosa in prostate cancer patients treated with radiotherapy: phase I/II randomized placebo-controlled trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2014Trial
- Combined Molecular Hydrogen and Vitamin C Treatment in Irradiated Normal and Cancer Cell Models: An Exploratory In Vitro Study and Case Reports.Medical sciences (Basel, Switzerland) · 2026Article
- YK-4-250 mitigates gastrointestinal radiation syndrome and promotes overall survival following partial body radiation injury.Scientific reports · 2026Article
- Mechanistic trends and therapeutic targets in Radiation-Induced apoptosis: A bibliometric and translational mapping.Radiation and environmental biophysics · 2026Review
- Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis.Cancers · 2025Review
- Historical view of the effects of radiation on cancer cells.Oncology reviews · 2025Review
- Immuno-protective impact and clinical translation of radioprotective agents in cancer radiotherapy.Frontiers in immunology · 2025Review
- Role of Grape (Indian journal of clinical biochemistry : IJCB · 2025Article
- Pharmacological Features and Therapeutic Implications of Plumbagin in Cancer and Metabolic Disorders: A Narrative Review.Nutrients · 2024Review
- Natural Guardians: Natural Compounds as Radioprotectors in Cancer Therapy.International journal of molecular sciences · 2024Review
- Recombinant Human Keratinocyte Growth Factor Ameliorates Cancer Treatment-Induced Oral Mucositis on a Chip.Advanced healthcare materials · 2024Article
- Nanozyme-Engineered Hydrogels for Anti-Inflammation and Skin Regeneration.Nano-micro letters · 2024Review
- miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway.Breast cancer (Tokyo, Japan) · 2023Article
- Inducing apoptosis by using microRNA in radio-resistant prostate cancer: an in-silico study with an in-vitro validation.Molecular biology reports · 2023Article
- Involvement of extracellular vesicles in the progression, diagnosis, treatment, and prevention of whole-body ionizing radiation-induced immune dysfunction.Frontiers in immunology · 2023Article
- Characterization of plasma exosomal microRNAs in responding to radiotherapy of human esophageal squamous cell carcinoma.Molecular medicine reports · 2022Article
- miR-302a-3p Promotes Radiotherapy Sensitivity of Hepatocellular Carcinoma by Regulating Cell Cycle via MCL1.Computational and mathematical methods in medicine · 2022Article
- Radioprotection of deinococcal exopolysaccharide BRD125 by regenerating hematopoietic stem cells.Frontiers in oncology · 2022Article
- Regulation and coordination of the different DNA damage responses inFrontiers in cell and developmental biology · 2022Review
- Rapamycin Ameliorates Radiation-Induced Testis Damage in Mice.Frontiers in cell and developmental biology · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to ionising radiation results in mutagenesis and cell death, and the clinical manifestations depend on the dose and the involved body area. Reducing carcinogenesis in patients treated with radiotherapy, exposed to diagnostic radiation or who are in certain professional groups is mandatory. The prevention or treatment of early and late radiotherapy effects would improve quality of life and increase cancer curability by intensifying therapies. Experimental and clinical data have given rise to new concepts and a large pool of chemical and molecular agents that could be effective in the protection and treatment of radiation damage. To date, amifostine is the only drug recommended as an effective radioprotectant. This review identifies five distinct types of radiation damage (I, cellular depletion; II, reactive gene activation; III, tissue disorganisation; IV, stochastic effects; V, bystander effects) and classifies the radioprotective agents into five relevant categories (A, protectants against all types of radiation effects; B, death pathway modulators; C, blockers of inflammation, chemotaxis and autocrine/paracrine pathways; D, antimutagenic keepers of genomic integrity; E, agents that block bystander effects). The necessity of establishing and funding central committees that guide systematic clinical research into evaluating the novel agents revealed in the era of molecular medicine is stressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.